Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA's CRL

John Carroll

Editor & Founder

The FDA’s recent slapdown of Gilead’s rheumatoid arthritis JAK filgotinib didn’t even slightly delay its arrival in 2 big world markets. The EC stamped its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA's CRL

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Major PBM reforms feature in Congress' year-end spending bill

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Gilead wins a block­buster con­so­la­tion prize with EC, Japan­ese ap­provals for fil­go­tinib — but that bare­ly soft­ens the blow of the FDA's CRL

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA's CRL

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Major PBM reforms feature in Congress' year-end spending bill

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study